- Home
- USNA vs REPL Comparison
USNA vs REPL Comparison
Compare USNA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USNA
- REPL
- Stock Information
- Founded
- USNA 1992
- REPL 2015
- Country
- USNA United States
- REPL United States
- Employees
- USNA N/A
- REPL N/A
- Industry
- USNA Medicinal Chemicals and Botanical Products
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- USNA Health Care
- REPL Health Care
- Exchange
- USNA Nasdaq
- REPL Nasdaq
- Market Cap
- USNA 565.5M
- REPL 547.0M
- IPO Year
- USNA 1996
- REPL 2018
- Fundamental
- Price
- USNA $20.88
- REPL $4.50
- Analyst Decision
- USNA Hold
- REPL Hold
- Analyst Count
- USNA 1
- REPL 9
- Target Price
- USNA $36.00
- REPL $6.67
- AVG Volume (30 Days)
- USNA 189.4K
- REPL 3.5M
- Earning Date
- USNA 10-21-2025
- REPL 11-11-2025
- Dividend Yield
- USNA N/A
- REPL N/A
- EPS Growth
- USNA N/A
- REPL N/A
- EPS
- USNA 1.80
- REPL N/A
- Revenue
- USNA $899,221,000.00
- REPL N/A
- Revenue This Year
- USNA $13.94
- REPL N/A
- Revenue Next Year
- USNA $7.95
- REPL N/A
- P/E Ratio
- USNA $11.63
- REPL N/A
- Revenue Growth
- USNA 2.75
- REPL N/A
- 52 Week Low
- USNA $19.88
- REPL $2.68
- 52 Week High
- USNA $41.84
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- USNA 23.23
- REPL 46.16
- Support Level
- USNA $19.88
- REPL $4.30
- Resistance Level
- USNA $21.46
- REPL $5.01
- Average True Range (ATR)
- USNA 0.97
- REPL 0.28
- MACD
- USNA -0.55
- REPL 0.08
- Stochastic Oscillator
- USNA 12.26
- REPL 42.53
About USNA USANA Health Sciences Inc.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.